Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 275 recruiting now early-phase tilt #4 of 28,963 conditions

Prostate Cancer: early-phase trial registry

275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4 of 28,963 conditions by registered trial count.

749 US clinical trials · 275 currently recruiting · #4 of 28,963 conditions by registered trial count

Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.

Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.

Open enrollment, early-phase tilt

Prostate Cancer has 749 registered US clinical trials, 275 of them open to new participants right now, about 37% of the total.

275
recruiting participants now
37%
of trials open to enrollment
75
in Phase 3-4 (later-stage)
53
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #4 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostate Cancer recruits in line with its size-band peers.

    275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Prostate Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.

  3. Typical Prostate Cancer enrolment sits around 82 participants.

    Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.

  4. Prostate Cancer research is mostly interventional.

    628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1156Phase 2188Phase 362Phase 413

Open and recent trials

749 total, page 14 of 15

COMPLETED Phase 2 29 participants

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Benaroya Research Institute

NCT00242918

COMPLETED Phase 1 28 participants

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

M.D. Anderson Cancer Center

NCT00038194

COMPLETED Phase 1 27 participants

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

University of Kansas Medical Center

NCT00669162

COMPLETED Phase 1 27 participants

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

University of Southern California

NCT00574769

COMPLETED NA 27 participants

Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca

Virginia Commonwealth University

NCT06250751

COMPLETED 27 participants

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

University of Medicine and Dentistry of New Jersey

NCT00176579

COMPLETED NA 27 participants

Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

M.D. Anderson Cancer Center

NCT02135484

COMPLETED Phase 1 27 participants

XL-184+Abiraterone in Post-Chemo CRPC

Dana-Farber Cancer Institute

NCT01574937

COMPLETED NA 26 participants

Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients With Intermediate Risk Localized Prostate Cancer

Francis Medical

NCT04087980

COMPLETED Phase 2 25 participants

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

University of Arizona

NCT00003307

COMPLETED 25 participants

Genetic Investigation of Solid Tumors Cohort

Scripps Translational Science Institute

NCT01005225

COMPLETED Phase 1 25 participants

Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer

University of California, Davis

NCT02339168

COMPLETED 25 participants

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Vanderbilt-Ingram Cancer Center

NCT00897793

COMPLETED Phase 2 25 participants

Study Using CP-461 to Treat Advanced Prostate Cancer

Astellas Pharma

NCT00036075

COMPLETED Phase 2 24 participants

Satraplatin and Prednisone to Treat Prostate Cancer

National Cancer Institute (NCI)

NCT00634647

COMPLETED Phase 2 24 participants

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

National Cancer Institute (NCI)

NCT01867424

COMPLETED Phase 1 24 participants

A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy

Intuitive Surgical

NCT04574401

COMPLETED NA 24 participants

Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects

BioProtect

NCT00918229

COMPLETED Phase 1 23 participants

Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT03793543

COMPLETED NA 23 participants

Internal Radiation Therapy in Treating Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT00573833

COMPLETED Phase 1 23 participants

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals

NCT03199586

COMPLETED Phase 1 23 participants

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

Tyme

NCT02796898

COMPLETED Phase 2 21 participants

Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA

University of Colorado, Denver

NCT01521949

COMPLETED NA 21 participants

MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer

NYU Langone Health

NCT02303054

COMPLETED NA 21 participants

Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer

Brown University

NCT01083771

COMPLETED Phase 1 21 participants

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT00003819

COMPLETED NA 20 participants

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

National Cancer Institute (NCI)

NCT00082147

COMPLETED Phase 1 20 participants

Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography

Queen's Medical Center

NCT01310192

COMPLETED NA 20 participants

Early Assessment of Treatment Response Using Functional Diffusion Mapping

University of Michigan Rogel Cancer Center

NCT02064283

COMPLETED Phase 2 20 participants

PSMA Imaging of Localized Prostate Cancer

Weill Medical College of Cornell University

NCT03675451

COMPLETED Phase 1 20 participants

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

Cancer Targeted Technology

NCT02916537

COMPLETED Phase 1 20 participants

Lycopene in Healthy Male Participants

National Cancer Institute (NCI)

NCT00450957

COMPLETED 20 participants

Prospective Evaluation of a Commercially Available Hydrogel Spacer

BioProtect

NCT05323747

COMPLETED Phase 1 20 participants

Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

The Cleveland Clinic

NCT00252941

COMPLETED Phase 1 20 participants

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

Duke University

NCT02036918

COMPLETED Phase 2 19 participants

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

Infinity Pharmaceuticals

NCT00564928

COMPLETED Phase 2 19 participants

Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy

ImaginAb

NCT02349022

COMPLETED Phase 2 19 participants

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

University of Michigan Rogel Cancer Center

NCT00150995

COMPLETED Phase 1 19 participants

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

Bracco Diagnostics

NCT02142608

COMPLETED Phase 1 18 participants

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Poniard Pharmaceuticals

NCT00465725

COMPLETED Phase 1 18 participants

Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer

Roswell Park Cancer Institute

NCT00217516

COMPLETED Phase 1 18 participants

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Pfizer

NCT04803305

COMPLETED 18 participants

Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

Kansas State University

NCT03275181

COMPLETED Phase 1 17 participants

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

University of Michigan Rogel Cancer Center

NCT02946008

COMPLETED Phase 2 16 participants

Digoxin for Recurrent Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

NCT01162135

COMPLETED Phase 1 16 participants

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00703638

COMPLETED NA 15 participants

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

Dana-Farber Cancer Institute

NCT02470910

COMPLETED Phase 1 15 participants

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

Memorial Sloan Kettering Cancer Center

NCT00698711

COMPLETED 15 participants

Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy

University of Vermont Medical Center

NCT02110667

COMPLETED Phase 1 15 participants

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

National Cancer Institute (NCI)

NCT00061347

← Previous Page 14 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 156
Phase 2 188
Phase 3 62
Phase 4 13

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Prostate Cancer right now

275 recruiting of 749 indexed (37% open).

Phase mix: 75 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (53 trials), 9 others listed. 50 shown below, recruiting first. #4 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Prostate Cancer?

PlainTrial tracks 749 US clinical trials for Prostate Cancer, of which 275 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Prostate Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.